Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Krystal Biotech (KRYS) stock drew attention after the company disclosed new information related to KB801, its investigational gene therapy for neurotrophic keratitis, in a patent filing response with the U.S. Patent and Trademark Office.
See our latest analysis for Krystal Biotech.
Against this backdrop, Krystal Biotech's share price has moved to US$363.28, with the stock up 7.86% over the past week and showing a 90 day share price return of 38.52%. The 1 year total shareholder return is 137.10%, pointing to strong momentum built over a longer period.
If this kind of biotech-driven move has your attention, it could be a good moment to see what else is on the radar and check out 41 healthcare AI stocks
Krystal Biotech now sits near its recent highs after the KB801 disclosure and index reshuffle, so the balance between upside potential and downside risk matters more than ever. Do the current fundamentals still justify this price tag?
Most Popular Narrative: 40% Overvalued
The most followed narrative puts Krystal Biotech's fair value at $361.67, which sits just below the last close of $363.28, and frames a rich growth story.
The analysts have a consensus price target of $361.67 for Krystal Biotech based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $1.0 billion, earnings will come to $552.3 million, and it would be trading on a PE ratio of 25.1x, assuming you use a discount rate of 7.1%.
There is a detailed growth path behind that fair value. It leans on rapid revenue expansion, higher margins, and a future earnings multiple above the wider biotech sector. You might want to examine which assumptions really carry the weight in this narrative.
Result: Fair Value of $361.67 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still meaningful risks for Krystal Biotech, including reliance on VYJUVEK and uncertainty around clinical outcomes and reimbursement for future KB801 and KB407 launches.
Find out about the key risks to this Krystal Biotech narrative.
Another View: Krystal Biotech Through a Cash Flow Lens
The analyst narrative suggests Krystal Biotech is about 40% overvalued around $363, based on earnings forecasts and future P/E assumptions. Our DCF model points in a very different direction. It indicates the stock trades well below an estimated future cash flow value of $1,081.28. Which story do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Krystal Biotech for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals around Krystal Biotech leave you uncertain, review the numbers now and decide where you stand with 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Krystal Biotech?
If Krystal Biotech has you thinking more broadly about opportunities, use this moment to scan fresh ideas instead of waiting for the next headline to move.
-
Target potential mispricing by reviewing companies flagged in the 49 high quality undervalued stocks .
-
Strengthen your income stream by assessing stocks in the 9 dividend fortresses .
-
Prioritize resilience and capital preservation by focusing on the 85 resilient stocks with low risk scores .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KRYS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
